High-dose versus low-dose inhaled levodopa (CVT-301) in patients with Parkinson disease for the treatment of OFF episodes: a meta-analysis of randomized controlled trials

High-dose versus low-dose inhaled levodopa (CVT-301) in patients with Parkinson disease for the treatment of OFF episodes: a meta-analysis of randomized controlled trials
Neurol Sci. 2022 Jul 30. doi: 10.1007/s10072-022-06298-z. Online ahead of print.ABSTRACTBACKGROUND: Levodopa is the most commonly used first-line drug for Parkinson's disease. However, during the period of medication, the generation of motor fluctuations affects the life quality of patients. CVT-301, as an inhaled levodopa for the treatment of OFF episodes, rose in response to this condition.METHODS: We systematically searched Medline, ... read more
Source: PubMedPublished on 2022-07-30By Zeya Yan